SG11202005021PA - Fcrn antibodies and methods of use thereof - Google Patents
Fcrn antibodies and methods of use thereofInfo
- Publication number
- SG11202005021PA SG11202005021PA SG11202005021PA SG11202005021PA SG11202005021PA SG 11202005021P A SG11202005021P A SG 11202005021PA SG 11202005021P A SG11202005021P A SG 11202005021PA SG 11202005021P A SG11202005021P A SG 11202005021PA SG 11202005021P A SG11202005021P A SG 11202005021PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- fcrn antibodies
- fcrn
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005021PA true SG11202005021PA (en) | 2020-07-29 |
Family
ID=65041911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005021PA SG11202005021PA (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11773168B2 (de) |
| EP (1) | EP3723802A1 (de) |
| JP (2) | JP7420720B2 (de) |
| KR (1) | KR20200098604A (de) |
| CN (1) | CN111712259A (de) |
| AU (1) | AU2018386193A1 (de) |
| BR (1) | BR112020011310A2 (de) |
| CA (1) | CA3085751A1 (de) |
| IL (1) | IL275070A (de) |
| SG (1) | SG11202005021PA (de) |
| WO (1) | WO2019118791A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016123521A2 (en) | 2015-01-30 | 2016-08-04 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| JP7420720B2 (ja) | 2017-12-13 | 2024-01-23 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| AU2020319897A1 (en) * | 2019-08-01 | 2022-02-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| KR20220148804A (ko) | 2020-01-08 | 2022-11-07 | 아르젠엑스 비브이 | 천포창 장애의 치료 방법 |
| AU2021292200A1 (en) * | 2020-06-17 | 2023-02-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| WO2023030501A1 (zh) * | 2021-09-03 | 2023-03-09 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| AR128284A1 (es) * | 2022-01-17 | 2024-04-10 | argenx BV | Métodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3192528A1 (de) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formularierung anti-il-6r antikörper-enthaltender lösungen die einen zucker als stabilisator beinhalten |
| WO2005013912A2 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of Newyork | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| US20090238820A1 (en) | 2005-03-08 | 2009-09-24 | Allan Corey M | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| EP1986690A4 (de) | 2006-01-25 | 2009-05-13 | Univ New York State Res Found | Antikörper gegen fcrn zur behandlung von auto-/alloimmunleiden |
| AU2007224631A1 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against IL-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| EP3670538A1 (de) | 2008-04-25 | 2020-06-24 | Dyax Corp. | Antikörper gegen fcrn und deren gebrauch |
| CA2766065C (en) | 2009-06-30 | 2020-07-21 | Research Development Foundation | Immunoglobulin fc polypeptides |
| KR102046666B1 (ko) * | 2011-05-25 | 2019-11-19 | 이나뜨 파르마 | 염증성 장애의 치료를 위한 항-kir 항체 |
| CA2837527C (en) | 2011-06-02 | 2019-05-28 | Dyax Corp. | Fc receptor binding proteins |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| WO2014099636A1 (en) | 2012-12-18 | 2014-06-26 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-tnf alpha antibody |
| EP3719122A1 (de) | 2013-05-02 | 2020-10-07 | Momenta Pharmaceuticals, Inc. | Sialylierte glycoproteine |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| WO2015167293A1 (en) | 2014-04-30 | 2015-11-05 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
| WO2016123521A2 (en) | 2015-01-30 | 2016-08-04 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| EP3294335B1 (de) * | 2015-05-12 | 2023-07-05 | Syntimmune Inc. | Humanisierte affinitätsgereifte anti-fcrn-antikörper |
| DK3491025T3 (da) * | 2016-07-29 | 2024-01-15 | Momenta Pharmaceuticals Inc | Fcrn-antistoffer og anvendelsesmetoder heraf |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| JP7420720B2 (ja) | 2017-12-13 | 2024-01-23 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| US20210139582A1 (en) | 2018-02-13 | 2021-05-13 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
| CR20210076A (es) | 2018-07-20 | 2021-09-02 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpo fcrn |
| WO2020023310A1 (en) | 2018-07-20 | 2020-01-30 | Williams Eva | Compositions of fcrn antibodies and methods of use thereof |
| MX2021004351A (es) | 2018-10-16 | 2021-05-31 | UCB Biopharma SRL | Metodo para el tratamiento de miastenia grave. |
| AU2020319897A1 (en) | 2019-08-01 | 2022-02-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| KR20230117575A (ko) | 2020-11-06 | 2023-08-08 | 모멘타 파머슈티컬스 인코포레이티드 | Fcrn 항체 및 이의 사용 방법 |
-
2018
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en unknown
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/de active Pending
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 KR KR1020207019955A patent/KR20200098604A/ko unknown
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 AU AU2018386193A patent/AU2018386193A1/en active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en active Pending
- 2023-10-13 JP JP2023177190A patent/JP2024016042A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018386193A8 (en) | 2020-07-02 |
| WO2019118791A1 (en) | 2019-06-20 |
| BR112020011310A2 (pt) | 2020-11-17 |
| JP7420720B2 (ja) | 2024-01-23 |
| US11773168B2 (en) | 2023-10-03 |
| JP2024016042A (ja) | 2024-02-06 |
| AU2018386193A1 (en) | 2020-06-25 |
| CN111712259A (zh) | 2020-09-25 |
| EP3723802A1 (de) | 2020-10-21 |
| CA3085751A1 (en) | 2019-06-20 |
| IL275070A (en) | 2020-07-30 |
| US20220064290A1 (en) | 2022-03-03 |
| JP2021506786A (ja) | 2021-02-22 |
| KR20200098604A (ko) | 2020-08-20 |
| US20240158509A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
| SI3618863T1 (sl) | Protitelesa proti tigitu in načini uporabe njih | |
| ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL272274A (en) | Antibodies 4H-7B methods for their use | |
| SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| IL252837B (en) | fcrn antibodies and methods of using them | |
| IL264528B1 (en) | fcrn antibodies and methods of using them | |
| IL275070A (en) | FCRN antibodies and methods of using them | |
| IL270214A (en) | Anti-sortilin antibodies and methods of using them | |
| IL265957A (en) | Anti-c1s antibodies and methods of using them | |
| IL268568A (en) | TRAILshort antibody and methods of use | |
| IL274221A (en) | Antibodies to ANTI-APOC3 and methods of use | |
| ZA202002144B (en) | Antibodies and methods of use | |
| IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use |